Literature DB >> 10467370

Adenovirus-mediated expresssion of the murine ecotropic receptor facilitates transduction of human hematopoietic cells with an ecotropic retroviral vector.

A C Nathwani1, D A Persons, S C Stevenson, P Frare, A McClelland, A W Nienhuis, E F Vanin.   

Abstract

One factor limiting the ability to modify human repopulating hematopoietic cells genetically with retroviral vectors is the relatively low expression of the cognate viral receptor. We have tested sequential transduction of human hematopoietic cells with an adenoviral vector encoding the ecotropic retroviral receptor followed by transduction with an ecotropic retroviral vector. Adenoviral transduction of K562 erythroleukemia cells was highly efficiently with >95% of cells expressing the ecotropic receptor at a multiplicity of infection (MOI) of 103with a correspondingly high transduction with a retroviral vector. Ecotropic receptor expression in CD34+ cells following transduction with adenoviral vectors was increased by at least two-fold (from 20 to 48%) by replacing the RSV promoter with the CMV E1a promoter, resulting in a parallel increase in retroviral transduction efficiency. Replacing the head portion of the fiber protein in conventional adenoviral vectors (serotype 5) with the corresponding portion from an adenoviral 3 serotype resulted in ecotropic receptor expression in 60% of CD34+ cells at an MOI of 104 and a retroviral transduction of 60% of hematopoietic clonogenic progenitors. The sequential transduction strategy also resulted in efficient transduction of the primitive CD34+CD38- subset suggesting that it may hold promise for genetic modification of human hematopoietic stem cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467370     DOI: 10.1038/sj.gt.3300974

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

1.  Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.

Authors:  C Brimer; J T Dalton; Z Zhu; J Schuetz; K Yasuda; E Vanin; M V Relling; Y Lu; E G Schuetz
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

2.  Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.

Authors:  J H McIntosh; M Cochrane; S Cobbold; H Waldmann; S A Nathwani; A M Davidoff; A C Nathwani
Journal:  Gene Ther       Date:  2011-06-30       Impact factor: 5.250

3.  Adaptation of chimeric retroviruses in vitro and in vivo: isolation of avian retroviral vectors with extended host range.

Authors:  E V Barsov; W S Payne; S H Hughes
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Enhancing transduction of the liver by adeno-associated viral vectors.

Authors:  A C Nathwani; M Cochrane; J McIntosh; C Y C Ng; J Zhou; J T Gray; A M Davidoff
Journal:  Gene Ther       Date:  2008-08-14       Impact factor: 5.250

5.  AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.

Authors:  Makiko Yasuda; David F Bishop; Mary Fowkes; Seng H Cheng; Lin Gan; Robert J Desnick
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.